国际生殖健康/计划生育杂志 ›› 2026, Vol. 45 ›› Issue (4): 311-317.doi: 10.12280/gjszjk.20260080

• 综述 • 上一篇    下一篇

短时受精联合早期补救卵胞质内单精子注射的精准应用

苑霞, 韩晓芳, 李弘()   

  1. 030012 太原山西医科大学第五临床医学院
  • 收稿日期:2026-02-14 出版日期:2026-07-15 发布日期:2026-07-27
  • 通讯作者: 李弘 E-mail:lh1461@sina.com

Precise Application of Short-Term Insemination Combined with Early Rescue Intracytoplasmic Sperm Injection

YUAN Xia, HAN Xiao-fang, LI Hong()   

  1. The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China
  • Received:2026-02-14 Published:2026-07-15 Online:2026-07-27
  • Contact: LI Hong E-mail:lh1461@sina.com

摘要:

常规体外受精(conventional in vitro fertilization,c-IVF)是目前临床应用最广泛的辅助生殖技术之一,但其5%~15%的完全受精失败(total fertilization failure,TFF)率仍是不可忽视的临床难题,可显著降低累积活产率,直接引发周期取消与胚胎资源匮乏,加重患者负担。短时受精联合早期补救卵胞质内单精子注射(early rescue intracytoplasmic sperm injection,E-RICSI)是预防c-IVF周期TFF的核心策略,通过3~6 h精卵共孵育联合第二极体排出情况监测,可及时干预受精障碍,规避卵母细胞体外老化风险,同时保留自然受精优势。经循证证实该技术可将TFF率降至1%以下,维持良好的正常受精率和优质囊胚形成率,其临床妊娠、累积活产结局及新生儿安全性均与常规卵胞质内单精子注射(intracytoplasmic sperm injection,ICSI)相当,兼具良好的卫生经济学效益。但该技术目前仍存在指征不统一、风险分层精准度不足、应用不规范等问题。综述该技术的循证医学研究、风险分层体系与临床决策路径,旨在为其规范化、精准化临床应用提供循证参考。

关键词: 体外受精, 精子注射,细胞质内, 风险评估与减低, 短时受精, 早期补救卵胞质内单精子注射

Abstract:

Conventional in vitro fertilization (c-IVF) is one of the most widely used assisted reproductive technologies in clinical practice. However, 5% to 15% of total fertilization failure (TFF) rate remains a non-negligible clinical challenge, which can significantly reduce the cumulative live birth rate, directly lead to cycle cancellation and embryo resource depletion, and impose a heavy burden on patients. The short-term insemination combined with early rescue intracytoplasmic sperm injection (E-RICSI) is the core strategy for preventing TFF in c-IVF cycles. By the co-incubating sperm and oocytes for 3 to 6 hours combined with monitoring of second polar body extrusion, this technique enables a timely intervention for fertilization disorders, avoids the risk of oocyte aging in vitro, and simultaneously preserves the advantages of natural fertilization. Evidence-based studies have confirmed that this technique can reduce the TFF rate to below 1%, maintain favorable normal fertilization rate and high-quality blastocyst formation rate. Its clinical pregnancy outcomes, cumulative live birth outcomes and neonatal safety are comparable to those of conventional intracytoplasmic sperm injection (ICSI), with good health economic benefits. Nevertheless, this technique still faces some problems such as inconsistent indications, insufficient accuracy of risk stratification, and non-standard clinical application. This article reviews the evidence-based progress, risk stratification system, and clinical decision-making pathway of this technique, aiming to provide evidence-based references for its standardized and precise clinical application.

Key words: Fertilization in vitro, Sperm injections, intracytoplasmic, Risk evaluation and mitigation, Short-term insemination, Early rescue intracytoplasmic sperm injection